The initial investment in mRNA Vaccines for GOAL 2050 will be generated from private investment in the Norvax AAA mRNA Vaccine Bond up to $800 million dollars.
The AAA bond finance will be used for development and manufacturing of transformative mRNA vaccines in the new UKvax Factory with modular localized mRNA vaccine factory scaling.
The new GOAL 2050 campaign is planned in cooperation with the mRNA Vaccine Consortium, The Vaccine Confidence Project and Global Public Health Stakeholders.
$800 million dollars is less than 3 DAYS COST of TB and HIV. ($350 million per day)